81
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Methylsulfonylpyrazolyl Oxadiazoles and Thiadiazoles as Potent, Orally Bioavailable Cannabinoid-1 Receptor Antagonists for the Treatment of Obesity

, , , , , , , , , & show all
Pages 947-967 | Published online: 19 Aug 2009
 

Abstract

Background: Since the cannabinoid receptor 1 (CB1) antagonist SR141716 (rimonabant) was previously reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. Discussion: In the present study, biarylpyrazole analogues based on a sulfur-containing pyrazole core coupled with 1,3,4-oxadiazole and 1,3,4-thiadiazole were synthesized and assayed for rat CB1 receptor binding affinity. Results: The structure–activity relationship studies to optimize pyrazole substituents as well as 1,3,4-oxadiazole or 1,3,4-thiadiazole rings led to four novel CB1 antagonists with IC50 values of approximately 1 nM for the rat CB1 receptor binding. Among these derivatives, we identified trifluoromethylcyclobutyl analogues 19e and 19l as promising precandidates for the development as anti-obesity agents.

Acknowledgements

We are grateful to Dr Eun Chul Huh for many valuable discussions throughout small molecule research programs at Central Research Laboratories, Green Cross Corp. (GCC).

Financial & competing interests disclosure

This research was in part (Park H-J and Yoo J) supported by a grant (CBM32-B2000-01-02-00) from the Center for Biological Modulators of the 21st Century Frontier R&D Program, the Ministry of Science, Republic of Korea. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Additional information

Funding

This research was in part (Park H-J and Yoo J) supported by a grant (CBM32-B2000-01-02-00) from the Center for Biological Modulators of the 21st Century Frontier R&D Program, the Ministry of Science, Republic of Korea. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.